NDAORALTABLET
Approved
Aug 2014
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
5
Data completeness
6/8 — Strong
TRIUMEQ (abacavir sulfate, dolutegravir sodium, lamivudine) by GSK is nucleoside reverse transcriptase inhibitors [moa]. Approved for hepatitis b virus nucleoside analog reverse transcriptase inhibitor [epc]. First approved in 2014.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIUMEQ is a fixed-dose combination tablet containing abacavir sulfate, dolutegravir sodium, and lamivudine, approved by the FDA on August 22, 2014. It is indicated for the treatment of HIV-1 infection in adult patients. The product works through a dual mechanism: nucleoside reverse transcriptase inhibitors (abacavir and lamivudine) and an integrase strand transfer inhibitor (dolutegravir). TRIUMEQ represents a complete once-daily regimen and is positioned as a first-line treatment option in the HIV antiretroviral therapy landscape.
$0.6BPart D
4.1 years to LOEMechanism of Action
Nucleoside Reverse Transcriptase Inhibitors
Pharmacologic Class:
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (5)
A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants
Started May 2021
33 enrolled
HIV Infections
To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers
Started Feb 2018
36 enrolled
HIV Infections
Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs
Started Nov 2016
33 enrolled
Human Immunodeficiency Virus
Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations
Started Nov 2015
27 enrolled
HIV Infections
Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany
Started Feb 2015
403 enrolled
HIV Infections
Worked on TRIUMEQ at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.